Literature DB >> 34462886

Heterogeneity in the diagnosis of plasmablastic lymphoma, plasmablastic myeloma, and plasmablastic neoplasm: a scoping review.

Hirotaka Mori1, Masahiko Fukatsu2, Hiroshi Ohkawara2, Yuka Oka3, Yuki Kataoka4,5,6,7, Shunsuke Taito6,8, Takayuki Ikezoe2.   

Abstract

The diagnosis of plasmablastic lymphoma (PBL), plasmablastic myeloma (PBM), and plasmablastic neoplasm (PBN) may be arbitrary in some cases because these entities can be indistinct. We conducted this scoping review to investigate heterogeneity in diagnostic criteria used in previous studies and validate the diagnostic results of previous diagnostic algorithms and the algorithm we developed, which also includes diagnosis of PBN. Using the PRISMA Extension for Scoping Reviews, we analyzed literature published between September 2017 and April 2020. We identified a total of 163 cases (128 PBL, 32 PBM, and 3 PBN) from 77 case reports and 8 case series. We found that diagnostic criteria in the literature varied for PBL but were consistent for PBM. Our algorithm was the first attempt to include PBN in a complete structure. The results of the three diagnostic algorithms varied significantly. Hematologists and pathologists should pay more attention to the differential diagnosis of PBL, PBM, and PBN.
© 2021. Japanese Society of Hematology.

Entities:  

Keywords:  Plasmablastic lymphoma; Plasmablastic myeloma; Plasmablastic neoplasm; Scoping review

Mesh:

Substances:

Year:  2021        PMID: 34462886     DOI: 10.1007/s12185-021-03211-w

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  116 in total

1.  Plasmablastic lymphoma versus plasmablastic myeloma: an ongoing diagnostic dilemma.

Authors:  Janice S Ahn; Ryan Okal; Jeffrey A Vos; Matthew Smolkin; Abraham S Kanate; Flavia G Rosado
Journal:  J Clin Pathol       Date:  2017-03-01       Impact factor: 3.411

Review 2.  The biology and treatment of plasmablastic lymphoma.

Authors:  Jorge J Castillo; Michele Bibas; Roberto N Miranda
Journal:  Blood       Date:  2015-01-30       Impact factor: 22.113

3.  Multiple bone lesions and hypercalcemia presented in diffuse large B cell lymphoma: mimicking multiple myeloma?

Authors:  Ping Chen; Bingzong Li; Wenzhuo Zhuang; Haiwen Huang; Hong Zhang; Jinxiang Fu
Journal:  Int J Hematol       Date:  2010-04-09       Impact factor: 2.490

4.  Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles.

Authors:  Francisco Vega; Chung-Che Chang; Leonard J Medeiros; Mark M Udden; Jeong Hee Cho-Vega; Ching-Ching Lau; Chris J Finch; Regis A Vilchez; David McGregor; Jeffrey L Jorgensen
Journal:  Mod Pathol       Date:  2005-06       Impact factor: 7.842

5.  Spontaneous tumor lysis syndrome in the setting of B-cell lymphoma.

Authors:  Mateusz Opyrchal; Travis Figanbaum; Amit Ghosh; Vincent Rajkumar; Sean Caples
Journal:  Case Rep Med       Date:  2010-03-10

6.  Hypercalcaemia, renal dysfunction, anaemia and bone lesions (CRAB) do not always represent multiple myeloma: diffuse large B cell lymphoma presenting with CRAB symptoms in a 69-year-old man.

Authors:  Hafez Mohammad Ammar Abdullah; Moataz Ellithi; Qazi Waqas; Arwyn Cunningham; Tony Oliver
Journal:  BMJ Case Rep       Date:  2019-08-04

7.  High serum erythropoietin and ferritin levels in conjunction with anemia response in malignant lymphoma.

Authors:  Sofia Omari; Alhossain Khalafallah; Mahmoud Ayesh; Ismail Matalka; Raji Al-Hadithi
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-05-16       Impact factor: 2.576

8.  Spontaneous Tumor Lysis Syndrome: A Case Report and Critical Evaluation of Current Diagnostic Criteria and Optimal Treatment Regimens.

Authors:  Alicia C Weeks; Michelle E Kimple
Journal:  J Investig Med High Impact Case Rep       Date:  2015-08-25

9.  Solitary plasmacytoma: population-based analysis of survival trends and effect of various treatment modalities in the USA.

Authors:  Nishitha Thumallapally; Ahmed Meshref; Mohammed Mousa; Terenig Terjanian
Journal:  BMC Cancer       Date:  2017-01-05       Impact factor: 4.430

View more
  1 in total

Review 1.  Plasmablastic lymphoma: An update.

Authors:  Jenique Bailly; Nicholas Jenkins; Dharshnee Chetty; Zainab Mohamed; Estelle R Verburgh; Jessica J Opie
Journal:  Int J Lab Hematol       Date:  2022-09       Impact factor: 3.450

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.